MX347257B - Solido de gamma-carbolinas fusionadas con heterociclos substituidos. - Google Patents
Solido de gamma-carbolinas fusionadas con heterociclos substituidos.Info
- Publication number
- MX347257B MX347257B MX2014007104A MX2014007104A MX347257B MX 347257 B MX347257 B MX 347257B MX 2014007104 A MX2014007104 A MX 2014007104A MX 2014007104 A MX2014007104 A MX 2014007104A MX 347257 B MX347257 B MX 347257B
- Authority
- MX
- Mexico
- Prior art keywords
- carbolines
- substituted heterocycle
- solid
- heterocycle fused
- fused gamma
- Prior art date
Links
- 125000000623 heterocyclic group Chemical group 0.000 title abstract 2
- 239000007787 solid Substances 0.000 title 1
- 239000013078 crystal Substances 0.000 abstract 2
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
- C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3606908P | 2008-03-12 | 2008-03-12 | |
| PCT/US2009/001608 WO2009114181A2 (en) | 2008-03-12 | 2009-03-12 | Substituted heterocycle fused gamma-carbolines solid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX347257B true MX347257B (es) | 2017-04-20 |
Family
ID=41065729
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014007104A MX347257B (es) | 2008-03-12 | 2009-03-12 | Solido de gamma-carbolinas fusionadas con heterociclos substituidos. |
| MX2010010024A MX2010010024A (es) | 2008-03-12 | 2009-03-12 | Solido de gamma-carbolinas fusionadas con heterociclos substituidos. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010010024A MX2010010024A (es) | 2008-03-12 | 2009-03-12 | Solido de gamma-carbolinas fusionadas con heterociclos substituidos. |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US8648077B2 (enExample) |
| EP (1) | EP2262505B1 (enExample) |
| JP (1) | JP5611846B2 (enExample) |
| KR (2) | KR20150140418A (enExample) |
| CN (2) | CN105237536A (enExample) |
| AU (1) | AU2009223701B2 (enExample) |
| CA (1) | CA2716730C (enExample) |
| DK (1) | DK2262505T3 (enExample) |
| ES (1) | ES2530090T3 (enExample) |
| HR (1) | HRP20141178T1 (enExample) |
| IL (3) | IL207772A0 (enExample) |
| MX (2) | MX347257B (enExample) |
| PL (1) | PL2262505T3 (enExample) |
| PT (1) | PT2262505E (enExample) |
| SI (1) | SI2262505T1 (enExample) |
| WO (1) | WO2009114181A2 (enExample) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2679754C (en) | 2007-03-12 | 2018-08-07 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines synthesis |
| SI2262505T1 (sl) | 2008-03-12 | 2015-03-31 | Intra-Cellular Therapies, Inc. | Substituirana heterociklirano zliti gama-karbolinska trdna snov |
| WO2009145900A1 (en) | 2008-05-27 | 2009-12-03 | Intra-Cellular Therapies, Inc. | Methods and compositions for sleep disorders and other disorders |
| US9107696B2 (en) * | 2008-08-06 | 2015-08-18 | Emory University | Method of embryo transfer that eliminates transferred air while hormonally inducing implantation and apparatus |
| RU2591194C2 (ru) | 2010-04-22 | 2016-07-10 | Интра-Селлулар Терапиз, Инк. | Органические соединения |
| JP2015514135A (ja) | 2012-04-14 | 2015-05-18 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 新規組成物および方法 |
| DK2968320T3 (da) | 2013-03-15 | 2021-02-01 | Intra Cellular Therapies Inc | Organiske forbindelser |
| CA3148303C (en) | 2013-12-03 | 2024-02-27 | Intra-Cellular Therapies, Inc. | Heterocycle fused gamma-carboline compounds for use in treatment of bipolar disorders |
| KR102421235B1 (ko) | 2014-02-13 | 2022-07-15 | 인사이트 코포레이션 | Lsd1 저해제로서 사이클로프로필아민 |
| CA2944755A1 (en) | 2014-04-04 | 2015-10-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
| CA2944512C (en) | 2014-04-04 | 2018-04-24 | Intra-Cellular Therapies, Inc. | Heterocycle fused gamma-carbolines for treatment of central nervous system disorders |
| UA122688C2 (uk) | 2015-04-03 | 2020-12-28 | Інсайт Корпорейшн | Гетероциклічні сполуки як інгібітори lsd1 |
| JP7427363B2 (ja) | 2015-08-12 | 2024-02-05 | インサイト・ホールディングス・コーポレイション | Ｌｓｄ１阻害剤の塩 |
| PT3407888T (pt) | 2016-01-26 | 2021-03-19 | Intra Cellular Therapies Inc | Compostos de piridopirroloquinoxalina, suas composições e utilizações |
| SI3407889T1 (sl) | 2016-03-25 | 2021-09-30 | Intra-Cellular Therapies, Inc. | Organske spojine in njihova uporaba v zdravljenju ali preprečevanju motenj centralnega živčnega sistema |
| EP3436016B1 (en) * | 2016-03-28 | 2022-04-27 | Intra-Cellular Therapies, Inc. | Novel co-crystals |
| EP3436455A4 (en) * | 2016-03-28 | 2019-09-04 | Intra-Cellular Therapies, Inc. | NOVEL SALTS AND CRYSTALS |
| US10682354B2 (en) | 2016-03-28 | 2020-06-16 | Intra-Cellular Therapies, Inc. | Compositions and methods |
| HUE057055T2 (hu) | 2016-08-09 | 2022-04-28 | Teva Pharmaceuticals Int Gmbh | Lumateperon-ditozilátsó szilárd halmazállapotú formái |
| JP7013454B2 (ja) * | 2016-10-12 | 2022-02-15 | イントラ－セルラー・セラピーズ・インコーポレイテッド | アモルファス固体分散体 |
| WO2018126143A1 (en) | 2016-12-29 | 2018-07-05 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2018126140A1 (en) | 2016-12-29 | 2018-07-05 | Intra-Cellular Therapies, Inc. | Organic compounds |
| IL304026B2 (en) | 2017-03-24 | 2024-11-01 | Intra Cellular Therapies Inc | A pharmaceutical preparation containing 1-(4-fluoro-phenyl)-4-((Sa10,Rb6)-3-D2-2,2-methyl-2, 3, a10, 10, 9, b6- hexahydro-H7, H1- Pyrido[3',4',:4,5]pyrrolo[3,2,1-de]quioxalin-8-yl)-butan-1-one and its uses |
| EP3609501A4 (en) | 2017-04-10 | 2020-08-19 | Dr. Reddy's Laboratories Limited | AMORPHIC FORM AND SOLID DISPERSIONS OF LUMATEPERONE P-TOSYLATE |
| JP7223742B2 (ja) | 2017-07-26 | 2023-02-16 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| US11427587B2 (en) | 2017-07-26 | 2022-08-30 | Intra-Cellular Therapies, Inc. | Organic compounds |
| CN111107847A (zh) * | 2017-09-26 | 2020-05-05 | 细胞内治疗公司 | 新的盐和晶体 |
| US11655251B2 (en) | 2017-11-27 | 2023-05-23 | Egis Gyogyszergyar Zrt. | Method for the production of lumateperone and its salts |
| CN109867674A (zh) * | 2017-12-05 | 2019-06-11 | 上海度德医药科技有限公司 | 一种取代的杂环稠合γ-咔啉的新盐及其制备方法和晶型 |
| US11980617B2 (en) | 2018-03-16 | 2024-05-14 | Intra-Cellular Therapies, Inc. | Methods of treating acute depression and/or acute anxiety |
| DK3768271T3 (da) | 2018-03-23 | 2026-03-02 | Intra Cellular Therapies Inc | Organiske forbindelser |
| IL277504B1 (en) | 2018-03-23 | 2026-02-01 | Intra Cellular Therapies Inc | Deuterium-converted ((sa10,rb6)-8-(3-(4-fluorophenoxy)propyl 6b, 7, 8, 9, 10, 10a-hexahydro-1h-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-82(h3)-one compounds, pharmaceutical composition containing them and their uses |
| JP7476115B2 (ja) * | 2018-06-06 | 2024-04-30 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 新規の塩および結晶 |
| WO2019237037A1 (en) | 2018-06-08 | 2019-12-12 | Intra-Cellular Therapies, Inc. | Novel methods |
| DK3609891T3 (da) * | 2018-06-11 | 2026-02-23 | Intra Cellular Therapies Inc | Syntese af substituerede heterocykliske fusionerede gamma-carboliner |
| AU2019288476A1 (en) | 2018-06-21 | 2021-03-18 | Aquestive Therapeutics, Inc. | System and method for making personalized individual unit doses containing pharmaceutical actives |
| US12144808B2 (en) | 2018-08-29 | 2024-11-19 | Intra-Cellular Therapies, Inc. | Compositions and methods |
| WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
| AU2019328528B2 (en) * | 2018-08-31 | 2025-01-23 | Intra-Cellular Therapies, Inc. | Novel methods |
| MX2021002321A (es) | 2018-08-31 | 2021-04-28 | Intra Cellular Therapies Inc | Nuevos metodos. |
| BR112021004053A2 (pt) | 2018-09-07 | 2021-05-25 | Aquestive Therapeutics, Inc. | composições de filme oral e formas de dosagem tendo perfis de dissolução de ativo precisos |
| WO2020112941A2 (en) | 2018-11-27 | 2020-06-04 | Teva Czech Industries S.R.O | Solid state forms of lumateperone salts and processes for preparation of lumateperone and salts thereof |
| ES3047409T3 (en) | 2018-12-17 | 2025-12-03 | Intra Cellular Therapies Inc | Substituted heterocycle fused gamma-carbolines synthesis |
| EP3898580A4 (en) | 2018-12-17 | 2022-08-10 | Intra-Cellular Therapies, Inc. | SYNTHESIS OF CONDENSED GAMMA-CARBOLINES WITH SUBSTITUTED HETEROCYCLE |
| EP3898221A4 (en) | 2018-12-17 | 2022-09-14 | Intra-Cellular Therapies, Inc. | ORGANIC CONNECTION |
| WO2020132474A1 (en) | 2018-12-21 | 2020-06-25 | Intra-Cellular Therapies, Inc. | Organic compound |
| WO2020132605A1 (en) | 2018-12-21 | 2020-06-25 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2020182978A1 (en) | 2019-03-13 | 2020-09-17 | Sandoz Ag | Crystalline salt of a 5-ht2a receptor antagonist |
| CN114072150A (zh) | 2019-07-07 | 2022-02-18 | 细胞内治疗公司 | 新方法 |
| JP2022549335A (ja) | 2019-09-25 | 2022-11-24 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 新規方法 |
| IL292487A (en) | 2019-11-01 | 2022-06-01 | Aquestive Therapeutics Inc | Compositions of medicinal meters and methods of treatment |
| CA3159389A1 (en) | 2019-11-14 | 2021-05-20 | Aquestive Therapeutics, Inc. | Multimodal compositions comprising diazepam and methods of treatment |
| EP4072554A4 (en) | 2019-12-11 | 2023-12-20 | Intra-Cellular Therapies, Inc. | ORGANIC CONNECTION |
| EP4744678A2 (en) | 2019-12-19 | 2026-05-20 | Intra Cellular Therapies Inc | LUMATEPERONE FOR THE TREATMENT OF SCHIZOPHRENIA |
| WO2022155544A1 (en) | 2021-01-15 | 2022-07-21 | Aquestive Therapeutics, Inc. | Prodrug compositions and methods of treatment |
| CA3210706A1 (en) | 2021-03-09 | 2022-09-15 | Alexander Mark Schobel | Dosage forms having equivalent biocomparable profiles |
| CN117425652A (zh) * | 2021-06-07 | 2024-01-19 | 细胞内治疗公司 | 新盐和晶体 |
| US12414948B2 (en) | 2022-05-18 | 2025-09-16 | Intra-Cellular Therapies, Inc. | Methods |
| IL316924A (en) | 2022-05-18 | 2025-01-01 | Intra Cellular Therapies Inc | Novel methods |
| WO2024088285A1 (zh) * | 2022-10-26 | 2024-05-02 | 上海枢境生物科技有限公司 | 一种杂环取代的稠合γ-咔啉类衍生物的甲磺酸盐、晶型及其制备方法和应用 |
| WO2024145659A1 (en) | 2022-12-30 | 2024-07-04 | Intra-Cellular Therapies, Inc. | Heterocycle fused gamma-carbolines acting on the serotonine 5-ht2a receptor |
| WO2024173901A1 (en) | 2023-02-17 | 2024-08-22 | Intra-Cellular Therapies, Inc. | Lumateperone and derivatives thereof for modulating the nervous system |
| WO2025111568A1 (en) | 2023-11-22 | 2025-05-30 | Intra-Cellular Therapies, Inc. | Lumateperone and analogues, as 5-ht2a or 5-ht2a/d2 receptor modulators, for use in the treatment of psychiatric disorders caused by viral, bacterial, or autoimmune encephalitis, and of psychiatric symptoms thereof |
| US20250352469A1 (en) | 2024-05-16 | 2025-11-20 | Intra-Cellular Therapies, Inc. | Novel compositions, devices, and methods |
| WO2026011166A1 (en) | 2024-07-03 | 2026-01-08 | Intra-Cellular Therapies, Inc. | Substituted heterocycles for use in the treatment of diseases involving the 5-ht2a receptor |
| WO2026011136A1 (en) | 2024-07-03 | 2026-01-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7071186B2 (en) * | 1999-06-15 | 2006-07-04 | Bristol-Myers Squibb Pharma Co. | Substituted heterocycle fused gamma-carbolines |
| AR024378A1 (es) | 1999-06-15 | 2002-10-02 | Du Pont Pharm Co | Gamma-carbolinas fusionadas heterociclicas sustituidas |
| US6713471B1 (en) | 1999-06-15 | 2004-03-30 | Bristol-Myers Squibb Pharma Company | Substituted heterocycle fused gamma-carbolines |
| FR2796644B1 (fr) * | 1999-07-23 | 2001-09-07 | Adir | Nouveaux derives de beta-carboline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| KR20060037391A (ko) * | 2003-07-21 | 2006-05-03 | 스미스클라인 비참 코포레이션 | (2Ｓ,4Ｓ)-4-플루오로-1-[4-플루오로-베타-(4-플루오로페닐)-Ｌ-페닐알라닐]-2-피롤리딘카르보니트릴 ｐ-톨루엔설폰산염 및 이의 무수 결정 형태 |
| CA2679754C (en) | 2007-03-12 | 2018-08-07 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines synthesis |
| SI2262505T1 (sl) | 2008-03-12 | 2015-03-31 | Intra-Cellular Therapies, Inc. | Substituirana heterociklirano zliti gama-karbolinska trdna snov |
| WO2009145900A1 (en) | 2008-05-27 | 2009-12-03 | Intra-Cellular Therapies, Inc. | Methods and compositions for sleep disorders and other disorders |
| RU2591194C2 (ru) | 2010-04-22 | 2016-07-10 | Интра-Селлулар Терапиз, Инк. | Органические соединения |
| JP2015514135A (ja) | 2012-04-14 | 2015-05-18 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 新規組成物および方法 |
| DK2968320T3 (da) | 2013-03-15 | 2021-02-01 | Intra Cellular Therapies Inc | Organiske forbindelser |
-
2009
- 2009-03-12 SI SI200931092T patent/SI2262505T1/sl unknown
- 2009-03-12 PT PT97189518T patent/PT2262505E/pt unknown
- 2009-03-12 DK DK09718951.8T patent/DK2262505T3/en active
- 2009-03-12 HR HRP20141178AT patent/HRP20141178T1/hr unknown
- 2009-03-12 AU AU2009223701A patent/AU2009223701B2/en active Active
- 2009-03-12 PL PL09718951T patent/PL2262505T3/pl unknown
- 2009-03-12 EP EP09718951.8A patent/EP2262505B1/en active Active
- 2009-03-12 MX MX2014007104A patent/MX347257B/es unknown
- 2009-03-12 CA CA2716730A patent/CA2716730C/en active Active
- 2009-03-12 JP JP2010550697A patent/JP5611846B2/ja active Active
- 2009-03-12 KR KR1020157034267A patent/KR20150140418A/ko not_active Withdrawn
- 2009-03-12 KR KR1020107022312A patent/KR101610977B1/ko active Active
- 2009-03-12 US US12/922,056 patent/US8648077B2/en active Active
- 2009-03-12 WO PCT/US2009/001608 patent/WO2009114181A2/en not_active Ceased
- 2009-03-12 CN CN201510456013.4A patent/CN105237536A/zh active Pending
- 2009-03-12 ES ES09718951.8T patent/ES2530090T3/es active Active
- 2009-03-12 CN CN200980108387.XA patent/CN102046175B/zh active Active
- 2009-03-12 MX MX2010010024A patent/MX2010010024A/es active IP Right Grant
-
2010
- 2010-08-24 IL IL207772A patent/IL207772A0/en unknown
-
2014
- 2014-02-11 US US14/177,689 patent/US9199995B2/en active Active
-
2015
- 2015-11-30 US US14/954,845 patent/US9586960B2/en not_active Ceased
-
2018
- 2018-11-28 IL IL263338A patent/IL263338A/en unknown
-
2019
- 2019-03-06 US US16/294,607 patent/USRE48825E1/en active Active
-
2022
- 2022-01-09 IL IL289706A patent/IL289706A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2009114181A3 (en) | Substituted heterocycle fused gamma-carbolines solid | |
| PH12012500674A1 (en) | Heterocyclic compounds useful as pdk1 inhibitors | |
| EA201171151A1 (ru) | Кристаллические трипептидные ингибиторы эпоксикетон-протеазы | |
| MX2012007710A (es) | Alfa-amilasas. | |
| GB0800315D0 (en) | Method of replying to an electronically-received message | |
| MX2020001497A (es) | Sintesis de gamma-carbolinas fusionadas con heterociclo substituido. | |
| MX2011008864A (es) | Tetrahidroazolopirazinas sulfoniladas y su uso como productos medicinales. | |
| ZA201204031B (en) | Compounds, compositions and methods of using same for modulating uric acid levels | |
| MX2011009369A (es) | 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3. | |
| CL2009000503A1 (es) | Proceso de preparacion de compuestos derivados de acido 2-amino-5-cianobenzoico-3-sustituidos o 1h-pirazol-5-carboxamida. | |
| MX2011014019A (es) | Derivados de diazahomoadamantano y sus metodos de uso. | |
| ZA201202613B (en) | Spiro-condensed cyclohexane derivatives as hsl inhibitors useful for the treatment of diabetes | |
| MX2010004570A (es) | Metodos para la produccion de sal. | |
| ZA201404327B (en) | Composition comprising block cocondensates of propylfunctional alkaline siliconates and silicates, and method for the production thereof | |
| MX2011012623A (es) | Construcciones de casb7439. | |
| MX2011008662A (es) | 2-mercapto-3-aminopiridinas sustituidas como moduladores de kcnq2/3. | |
| MX2011009338A (es) | 3-amino-2-mercaptoquinolinas sustituidas como moduladores de kcnq2/3. | |
| EA201001870A1 (ru) | Новые кристаллические формы рабепразола натрия | |
| WO2009062659A3 (en) | Polymorphs of enantiopure erdosteine | |
| EA201001353A1 (ru) | Гидробромид ивабрадина | |
| IL212850A0 (en) | Novel method for the preparation of granulates of active constituents, and granulates as obtained | |
| WO2012063115A3 (en) | Process for the preparation of rosuvastatin calcium via novel amine intermediate | |
| EA201190256A1 (ru) | Способ снижения уровня убиквитинилированных белков | |
| MX2010003056A (es) | Polimorfos de valomaciclovir. | |
| WO2011100282A3 (en) | Imatinib mesylate polymorphs |